Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulati
This is a single center, prospective and observational study conducted in three stages to predict the NSCLC lymph node metastasis based on ctDNA/specific methylation molecular features combined with PET-CT imaging features and intervention study.
| Condition(s) | Carcinoma, Non-small Cell Lung Cancer |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | This is a single center, prospective and observational study conducted in three stages to predict the NSCLC lymph node metastasis based on ctDNA/specific methylation molecular features combined with PET-CT imaging features and intervention study. |
| Who can participate | Inclusion Criteria: 1. Provision of informed consent prior to study initiation. 2. Age between 18 and 75 years. 3. Preoperative clinical evaluation indicating non-small cell lung cancer (NSCLC) stage I-IIIB (without initial treatment sought). 4. Newly treated patients who have consented to undergo surgery. 5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1. Exclusion Criteria: 1. Non-small cell lung cancer (NSCLC) histopathologically determined to be other than stage I-IIIB following surgical evaluation. 2. Presence of other active malignant tumor diseases. 3. Evidence of any serious or uncontrolled systemic illness, including uncontrolled hypertension and active bleeding, as assessed by the investigator, which may contribute to reluctance to participate in t |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Lead sponsor | Shanghai Chest Hospital |
| Locations | Shanghai, China |
| Start date | 2023-12-15 |
| NCT ID | NCT06358222 |
| Official listing | https://clinicaltrials.gov/study/NCT06358222 |